<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033955</url>
  </required_header>
  <id_info>
    <org_study_id>001 CHAT 2009</org_study_id>
    <nct_id>NCT01033955</nct_id>
  </id_info>
  <brief_title>Collaborative H1N1 Adjuvant Treatment Pilot Trial</brief_title>
  <acronym>CHAT</acronym>
  <official_title>Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Critical Care Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Agency of Canada (PHAC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Critical Care Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design: A, multinational, double blind, placebo-controlled pilot RCT involving 80
      patients in the general ICUs of 30 centres. Most patients will be recruited from within
      Canada; however cases will be recruited from international sites. This study will be
      conducted under the auspices of the Canadian Critical Care Trials Group (CCCTG) and the
      International Forum for Acute Care Trialists (InFACT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: The primary objective of the CHAT Pilot Trial is to assess our ability to
      recruit the desired patient population (i.e., the proportion of eligible patients enrolled in
      the trial), and to conduct a scientifically rigorous international RCT under pandemic
      circumstances.

      Secondary Objectives: To evaluate (i) adherence to the medication administration regimen.
      (ii) the ability for research staff to collect the required primary and secondary endpoints
      for the planned full CHAT trial, (iii) the number of study withdrawals due to administration
      of open-label statins and withdrawals of consent and (iv) the impact of the approved consent
      model on recruitment rates.

      Study Methods (Overview): Using a web-based randomization system patients, research
      coordinators will assign critically ill adults treated with antiviral medication for &lt; or
      equal to 72 hours and requiring mechanical ventilation to one of two treatment strategies
      (rosuvastatin or placebo) for 14 days. Given the need to recruit patients into the CHAT Trial
      under pandemic conditions, when family members may not be present to provide written informed
      consent, we will request either a waiver of consent or deferred consent from Research Ethics
      Boards (REBs) at participating centres. The Keenan Research Centre/Li Ka Shing Knowledge
      Institute (St Michael's Hospital, Toronto, Ontario) will be the study Methods Centre.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    H1N1 pandemic concluded in early 2010
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eligible patients enrolled in the CHAT Pilot Trial.</measure>
    <time_frame>anticipated 6 months (duration of pandemic)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to the medication regimen as outlined in the study protocol.</measure>
    <time_frame>14 day treatment course</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of completed primary and secondary endpoints collected for the planned full CHAT trial</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of study withdrawals due to administration of open label statins and consent withdrawals</measure>
    <time_frame>anticipated 6 month study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Critically Ill</condition>
  <condition>H1N1/Influenza Infection</condition>
  <arm_group>
    <arm_group_label>Drug (Rosuvastatin) Crestor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first dose of encapsulated study drug or placebo (day 1) will be administered within 4 hours of randomization as a loading dose of 40 mg. The placebo will be identical in appearance to Rosuvastatin. Thereafter, doses of 20 mg will be administered daily starting on the next calendar day at 10 pm daily (+/- 4 hours) as a maintenance dose from days 2 to 14. If the patient is of Asian descent, is &lt;18 years, or serum creatinine is greater than or equal to 248 Î¼mol/L (2.8 mg/dL) dose adjustments will be made according to a dose adjustment algorithm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An identical appearing placebo will be administered to patients in the second study arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)</description>
    <arm_group_label>Drug (Rosuvastatin) Crestor</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>identical appearing encapsulated placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Critically ill adult patients &gt; or equal to 16 years of age admitted to an adult ICU
             for any reason with suspected, probable or confirmed influenza infection

          2. Requiring mechanical ventilation (invasive or non-invasive)

          3. Receiving antiviral therapy (any medication at any dose and for any intended duration)
             for &lt; or equal to 72 hours

          4. Attending physician or intensivist must have a 'moderate' to 'high' index of suspicion
             for influenza

        Exclusion Criteria:

          1. Age &lt; 16 years

          2. Do not resuscitate or re-intubate order documented on chart or anticipated withdrawal
             of life support

          3. Weight &lt; 40 kg

          4. Unable to receive or unlikely to absorb enteral study drug (e.g. incomplete or
             complete bowel obstruction, intestinal ischemia, infarction, short bowel syndrome)

          5. Rosuvastatin specific exclusions:

               -  Already receiving a statin (Atorvastatin, Lovastatin, Simvastatin, Pravastatin,
                  Rosuvastatin)

               -  Allergy or intolerance to statins

               -  Receiving niacin, fenofibrate, cyclosporine, gemfibrozil, lopinavir, ritonavir or
                  planned use of oral contraceptives or estrogen therapy during the ICU stay

               -  CK exceeds 10 times ULN or ALT exceeds 8 times the ULN

          6. Severe chronic liver disease (Child-Pugh Score 11-15)

          7. Previous enrollment in this trial

          8. Pregnancy or breast feeding

          9. At the time of enrollment, patients must not have received &gt;72 hours of antiviral
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Marshall, MD, FRCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen EA Burns, MD,FRCPC,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3B 0Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke (CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>critical care</keyword>
  <keyword>H1N1/influenza infection</keyword>
  <keyword>respiration</keyword>
  <keyword>ventilation, artificial</keyword>
  <keyword>critically ill patients</keyword>
  <keyword>invasive mechanical ventilation</keyword>
  <keyword>H1N1/influenza infection (suspected, probable or confirmed)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

